“Farber Disease Epidemiology” report has been added to DelveInsight
Overview of Farber Disease epidemiology, pathophysiology, various diagnostic approaches, and treatment algorithm, including detailed chapters for marketed products and emerging therapies
Download free sample copy here- https://www.delveinsight.com/sample-request/farbers-disease-epidemiology-insight
Farber Disease Overview
Farber’s disease is a rare inherited condition involving the breakdown and use of fats in the body. In affected individuals, lipids accumulate abnormally in cells and tissues throughout the body, particularly around the joints. The deficiency of an enzyme is called ceramidase resulting in the harmful accumulation of certain chemicals in the body, which causes damage and inflammation.
Farber Disease Geography Covered
Key facts of Farber Disease epidemiology report
Farber Disease epidemiology Segmentation
Farber Disease Prevalent Population
Farber lipogranulomatosis is a rare disorder. About 80 cases have been reported worldwide. Most children with the classic form of Farber’s disease die by age 2, usually from lung disease.
Farber Disease Treatment
Treatment may require the coordinated efforts of a team of specialists. Pediatricians, physicians who specialize in the diagnosis and treatment of neurological disorders in children (pediatric neurologists), neurologists, physicians who specialize in the diagnosis and treatment of disorders of the bones and skeleton (orthopedists), physicians who specialize in the diagnosis and treatment of eye disorders (ophthalmologists), physicians who specialize in the diagnosis and treatment of skin disorders (dermatologists), speech pathologists, physical therapists, pain specialists, and other healthcare professionals may need to systematically and comprehensively plan treatment.
Farber Disease Epidemiology Growth
Researchers are studying enzyme replacement therapy (ERT) for lysosomal storage diseases such as ASAH1-related disorders. ERT involves replacing a missing enzyme in individuals who are deficient or lack the particular enzyme in question. Synthetic versions of missing enzymes have been developed and used to treat individuals with certain lysosomal diseases including Hurler syndrome, Fabry disease, and Gaucher disease. Clinical trials are necessary to determine whether ERT will be safe and effective for the treatment of ASAH1-related disorders.
Farber Disease Report Scope
Following is the TOC of Farber Disease Epidemiology Report
1. Key Insights
2. Farber Disease: Epidemiology Overview at a Glance
3. Organizations
4. Executive Summary
5. Disease Overview: Farber Disease
6. Epidemiology and Patient Population
7. 7MM Epidemiology of Farber Disease
8. Bibliography
9. Appendix
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
What are the reasons to buy this report?
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Vinita Rakheja Email: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: www.delveinsight.com/